1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023

Summary

Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in developed countries. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified into dry AMD (geographic atrophy) and wet AMD (neovascular).

GlobalData epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.

GlobalData’s epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD; GlobalData epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.

Scope

- The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
- The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
1 Table of Contents
2 Introduction 6
2.1 Catalyst 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 9
3.3.1 US 9
3.3.2 5EU 10
3.3.3 Japan 10
3.4 Forecast Methodology 11
3.4.1 Sources Used 12
3.4.2 Forecast Assumptions and Methods 14
3.5 Epidemiological Forecast for AMD (2013-2023) 18
3.5.1 Total Prevalent Cases of AMD 18
3.5.2 Age-Specific Total Prevalent Cases of AMD 19
3.5.3 Sex-Specific Total Prevalent Cases of AMD 21
3.5.4 Age-Standardized Total Prevalence of AMD 23
3.5.5 Total Prevalent Cases of AMD by Stage 24
3.5.6 Total Prevalent Cases of Late AMD by Subtype 26
3.6 Discussion 28
3.6.1 Epidemiological Forecast Insight 28
3.6.2 Limitations of the Analysis 29
3.6.3 Strengths of the Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 34
4.2.1 Epidemiologists 34
4.2.2 Reviewers 34
4.2.3 Acting Director of Epidemiology 35
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 37
4.4 About EpiCast 37
4.5 Disclaimer 37

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for AMD 8
Table 2: Diagnostic Criteria for AMD 11
Table 3: 7MM, Sources of AMD Prevalence Data 12
Table 4: 7MM, Total Prevalent Cases of AMD, Ages ?50 Years, Both Sexes, N, 2013-2023 18
Table 5: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013 20
Table 6: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ?50 Years, N (Row %), 2013 22
Table 7: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ?50 Years, N (Row %), 2013 25
Table 8: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ?50 Years, N (Row %), 2013 27

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of AMD, Ages ?50 Years, Both Sexes, N, 2013-2023 19
Figure 2: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013 21
Figure 3: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ?50 Years, N, 2013 23
Figure 4: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ?50 Years, by Sex, 2013 24
Figure 5: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ?50 Years, N, 2013 26
Figure 6: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ?50 Years, N, 2013 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.